HPM Partners LLC Buys 7,270 Shares of Boston Scientific Co. (BSX)

HPM Partners LLC raised its stake in shares of Boston Scientific Co. (NYSE:BSX) by 5.5% in the fourth quarter, Holdings Channel reports. The institutional investor owned 139,256 shares of the medical equipment provider’s stock after buying an additional 7,270 shares during the quarter. HPM Partners LLC’s holdings in Boston Scientific were worth $3,452,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Truewealth LLC purchased a new position in Boston Scientific during the fourth quarter valued at $116,000. Icon Wealth Partners LLC purchased a new position in Boston Scientific during the fourth quarter valued at $117,000. Valeo Financial Advisors LLC purchased a new position in Boston Scientific during the third quarter valued at $138,000. Steward Partners Investment Advisory LLC purchased a new position in Boston Scientific during the third quarter valued at $139,000. Finally, Cerebellum GP LLC purchased a new position in Boston Scientific during the fourth quarter valued at $126,000. Institutional investors and hedge funds own 90.67% of the company’s stock.

How to Become a New Pot Stock Millionaire

In related news, SVP John Bradley Sorenson sold 1,950 shares of Boston Scientific stock in a transaction on Monday, March 5th. The stock was sold at an average price of $27.43, for a total value of $53,488.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael P. Phalen sold 15,835 shares of Boston Scientific stock in a transaction on Friday, December 29th. The stock was sold at an average price of $25.25, for a total value of $399,833.75. The disclosure for this sale can be found here. Insiders sold 174,276 shares of company stock valued at $4,592,464 in the last ninety days. 0.74% of the stock is currently owned by corporate insiders.

Shares of Boston Scientific Co. (NYSE BSX) opened at $28.54 on Friday. The company has a quick ratio of 0.49, a current ratio of 0.68 and a debt-to-equity ratio of 0.54. Boston Scientific Co. has a fifty-two week low of $24.02 and a fifty-two week high of $29.93. The company has a market capitalization of $39,239.96, a price-to-earnings ratio of 407.71, a P/E/G ratio of 2.07 and a beta of 0.82.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.34. Boston Scientific had a return on equity of 24.27% and a net margin of 1.15%. The company had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.39 billion. During the same quarter in the previous year, the company posted $0.30 earnings per share. Boston Scientific’s revenue was up 9.9% compared to the same quarter last year. analysts forecast that Boston Scientific Co. will post 1.37 EPS for the current fiscal year.

Several research analysts have recently weighed in on BSX shares. Canaccord Genuity decreased their price target on Boston Scientific from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, November 29th. Oppenheimer restated a “hold” rating on shares of Boston Scientific in a research note on Wednesday, November 29th. JPMorgan Chase & Co. restated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, November 29th. BTIG Research upgraded Boston Scientific from a “neutral” rating to a “buy” rating and set a $31.00 price target for the company in a research note on Thursday, November 30th. Finally, BMO Capital Markets restated a “buy” rating and issued a $31.00 price target on shares of Boston Scientific in a research note on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $31.06.

COPYRIGHT VIOLATION WARNING: “HPM Partners LLC Buys 7,270 Shares of Boston Scientific Co. (BSX)” was published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.themarketsdaily.com/2018/03/11/hpm-partners-llc-buys-7270-shares-of-boston-scientific-co-bsx.html.

Boston Scientific Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply